Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

New and recently launched products help offset Enbrel losses

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
2Q Revenues: $6.1 billion (+4%)
2Q Earnings: $2.3 billion (+7%)
YTD Revenues: $11.6 billion (+3%)
YTD Earnings: $4.6 billion (+9%)
Comments: New and recently launched products including Repatha, KYPROLIS, Prolia and XGEVA, had double-digit growth, helping to offset declines for Enbrel, down 11% to $1.3 billion, Aranesp, Epogen and Neupogen, down 12%, 14% and 26% respectively. Repatha sales increased 78% to $148 million driven primarily by higher demand, offset partially by selling price. BLINCYTO sales increased 40% to $60 million driven by higher demand. KYPROLIS sales increased 25% to $263 million driven by demand, offset partially by selling price. Prolia sales increased 21% to $610 million driven by higher demand. XGEVA sales were up 14% to $452 million. Neulasta sales were up 1% to $1.1 billion driven by an increase in selling price and, to a lesser extent, favorable changes in inventory, offset partially by lower unit demand. Sensipar/Mimpara sales were down 2% to $420 million driven by unfavorable changes in inventory and lower unit demand.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters